Log In

 

Company Name : Taro Pharmaceutical Industries Ltd.

Thursday, February 7, 2019 12:08PM IST (6:38AM GMT)

(BW)(NY-TARO-PHARMACEUTICAL)

Taro Provides Results for December 31, 2018


HAWTHORNE, N.Y., United States

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the three and nine months ended December 31, 2018.

 

Quarter ended December 31, 2018 Highlights ─ compared to December 31, 2017

 
  • Net sales of $176.4 million increased $20.9 million, mainly driven by a 13% increase in overall volumes.
  • Gross profit of $117.5 million (66.6% of net sales compared to 66.2%) increased $14.6 million.
  • Research and development (R&D) expenses of $14.7 million decreased $2.7 million.
  • Selling, marketing, general and administrative expenses (SG&A) of $23.9 million increased $2.1 million.
  • Operating income of $78.9 million (44.8% of net sales compared to 39.7%) increased $17.2 million.
  • Interest and other financial income increased $3.4 million to $8.4 million.
  • Foreign Exchange (FX) income of $30.7 million increased $27.0 million, principally the result of the strengthening of the U.S. dollar vs. the Canadian dollar. The FX impact is mainly balance sheet driven.
  • Tax expense of $25.8 million decreased $28.7 million; with the effective tax rate of 21.6% compared to 76.6%. The prior year quarter tax provision includes a $38.0 million expense for the estimated impact of the re-measurement of the Company's estimated net deferred tax asset at December 31, 2017, as a result of the Tax Cuts and Jobs Act. Excluding the impact from the one-time re-measurement, the Company's tax expense in the prior year quarter would have been approximately $16.4 million with an effective tax rate of 23.1%.
  • Net income attributable to Taro was $93.5 million compared to $18.0 million, a $75.5 million increase, resulting in diluted earnings per share of $2.40 compared to $0.45. Excluding the impact of the aforementioned one-time tax re-measurement in the prior year quarter, net income attributable to Taro would have been $54.8 million, or diluted earnings per share of $1.37.

Nine Months ended December 31, 2018 Highlights ─ compared to December 31, 2017

 
  • Net sales of $490.0 million increased $3.3 million, mainly driven by an 8.7% increase in overall volumes.
  • Gross profit of $326.2 million (66.6% of net sales compared to 70.8%) decreased $18.4 million.
  • R&D expenses of $42.7 million decreased $7.4 million principally due to the timing of clinical studies.
  • SG&A of $66.7 million increased $2.2 million.
  • Operating income of $220.8 million (45.1% of net sales compared to 46.9%) decreased $7.4 million.
  • Interest and other financial income increased $11.3 million to $25.3 million.
  • FX income of $34.7 million compared to FX expense of $48.5 million ─ a favorable impact of $83.2 million, principally the result of the strengthening of the U.S. dollar vs. the Canadian dollar. The FX impact is mainly balance sheet driven.
  • Tax expense of $59.1 million decreased $12.2 million; with the effective tax rate of 20.9% compared to 36.5%. Excluding the impact of the one-time tax re-measurement, the prior year tax expense would have been approximately $33.3 million with an effective tax rate of 17.0%.
  • Net income attributable to Taro was $223.3 million compared to $124.9 million, a $98.5 million increase, resulting in diluted earnings per share of $5.71 compared to $3.10. Excluding the impact of the one-time tax re-measurement, prior year net income attributable to Taro would have been $161.7 million, or diluted earnings per share of $4.01.

Cash Flow and Balance Sheet Highlights

 
  • Cash flow provided by operations for the nine months ended December 31, 2018, was $265.1 million compared to $225.8 million for the nine months ended December 31, 2017.
  • As of December 31, 2018, cash, including short-term bank deposits and marketable securities (both short and long-term) decreased $332.8 million to $1.3 billion from March 31, 2018. The decrease reflects the impact from the $500.0 million special dividend paid in December 2018 and the $72.2 million impact from the Company’s share repurchases.

Mr. Uday Baldota, Taro’s CEO stated, “While we are pleased with this quarters’ results and encouraged by the increase in our overall volumes, we are cautiously optimistic about viewing this as a continuing trend because the challenging generic landscape continues. The recently completed $250 million share repurchase program and payment of the $500 million special dividend, demonstrates our commitment to create shareholder value.” Mr. Baldota continued, “Our strong balance sheet and operating cash flow continues to provide us with the flexibility to consider a variety of operational and strategic growth opportunities to further maximize stockholder return over the longer term. We remain committed to maintain a disciplined capital allocation strategy.”

 

FDA Approvals and Filings

 

The Company recently received approvals from the U.S. Food and Drug Administration (“FDA”) for three Abbreviated New Drug Applications (“ANDAs”); Minoxidil Topical Aerosol, 5% (For Men), Tretinoin Cream USP, 0.1% and Tretinoin Cream USP, 0.05%. The Company currently has a total of twenty-seven ANDAs awaiting FDA approval, including eight tentative approvals.

 

Special Dividend - Returning Capital to Shareholders

 

On November 5, 2018, the Taro Board of Directors declared a $500 million special cash dividend on Taro ordinary shares. The special dividend was paid on December 28, 2018, to shareholders of record at the close of business on December 11, 2018.

 

Share Repurchase Program - Returning Capital to Shareholders

 

On January 15, 2019, the Company announced the completion of its $250.0 million share repurchase of ordinary shares. The Company bought back 2,493,378 of its ordinary shares in open market transactions, in accordance with a 10b5-1 program, at an average price of $100.28 per share. The repurchase program was announced by the Company on November 23, 2016, and was completed on January 11, 2019.

 

Taro to Discontinue Promoting U.S. Branded Products

 

The Board of Directors approved the Company to discontinue the promotion of its U.S. Branded products effective March 31, 2019. This action is expected to have an immaterial impact on the net sales of the Company.

 

The Company cautions that the foregoing financial information is unaudited and could be subject to change.

 

About Taro

 

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company’s website at www.taro.com.

 

SAFE HARBOR STATEMENT

 

The unaudited consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments necessary to present fairly the financial condition and results of operations of the Company.The unaudited consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 20-F, as filed with the SEC.

 

Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.These statements include, but are not limited to, statements that do not describe historical facts or that refer or relate to events or circumstances the Company “estimates,” “believes,” or “expects” to happen or similar language, and statements with respect to the Company’s financial performance, availability of financial information, and estimates of financial results and information for fiscal year 2019.Although the Company believes the expectations reflected in such forward-looking statements to be based on reasonable assumptions, it can give no assurances that its expectations will be attained.Factors that could cause actual results to differ include general domestic and international economic conditions, industry and market conditions, changes in the Company's financial position, litigation brought by any party in any court in Israel, the United States, or any country in which Taro operates, regulatory and legislative actions in the countries in which Taro operates, and other risks detailed from time to time in the Company’s SEC reports, including its Annual Reports on Form 20-F.Forward-looking statements are applicable only as of the date on which they are made.The Company undertakes no obligations to update, change or revise any forward-looking statement, whether as a result of new information, additional or subsequent developments or otherwise.

 

**Financial Tables Follow**

 
 
TARO PHARMACEUTICAL INDUSTRIES LTD.
SUMMARY CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

(U.S. dollars in thousands, except share data)
 
        Quarter Ended   Nine Months Ended  
        December 31,   December 31,  
       

2018

 

2017

 

2018

 

2017

 
Sales, net       $ 176,381     $ 155,461     $ 489,972     $ 486,697    
Cost of sales         58,838       52,545       163,785       142,118    
Gross profit         117,543       102,916       326,187       344,579    
                       
Operating Expenses:                      
Research and development         14,726       17,457       42,726       50,110    
Selling, marketing, general and administrative         23,883       21,830       66,650       64,421    
Settlements and loss contingencies               1,860       (4,000 )     1,860    
Operating income         78,934       61,769       220,811       228,188    
                       
Financial (income) expense, net:                      
Interest and other financial income         (8,388 )     (4,962 )     (25,302 )     (14,040 )  
Foreign exchange (income) expense         (30,702 )     (3,718 )     (34,706 )     48,506    
Other gain, net         1,398       622       1,910       1,430    
Income before income taxes         119,422       71,071       282,729       195,152    
Tax expense         25,752       54,411       59,083       71,262    
Income from continuing operations         93,670       16,660       223,646       123,890    
Net loss from discontinued operations attributable to Taro        

      (47 )           (239 )  
Net income         93,670       16,613       223,646       123,651    
Net income (loss) attributable to non-controlling interest         164       (1,359 )     303       (1,212 )  
Net income attributable to Taro       $ 93,506     $ 17,972     $ 223,343     $ 124,863    
                       
Net income per ordinary share from continuing operations attributable to Taro:                  
Basic and Diluted       $ 2.40     $ 0.45     $ 5.71     $ 3.10    
                       
Net loss per ordinary share from discontinued operations attributable to Taro:                  
Basic and Diluted       $

    $ (0.00 ) * $

    $ (0.00 ) *
                       
Net income per ordinary share attributable to Taro:                      
Basic and Diluted       $ 2.40     $ 0.45     $ 5.71     $ 3.10    
                       
Weighted-average number of shares used to compute net income per share:                  
Basic and Diluted         38,938,963       40,079,339       39,134,563       40,294,226    
                       
* Amount is less than $0.01                      
May not foot due to rounding.                      
                       

 

 
 
TARO PHARMACEUTICAL INDUSTRIES LTD.
SUMMARY CONSOLIDATED BALANCE SHEETS
(U.S. dollars in thousands)
             
        December 31,   March 31,
        2018   2018
ASSETS       (unaudited)   (audited)
CURRENT ASSETS:            
Cash and cash equivalents       $ 566,469   $ 576,611
Short-term and current maturities of long-term bank deposits             296,188
Marketable securities         488,582     549,821
Accounts receivable and other:            
Trade, net         223,791     206,455
Corporate tax receivable         11,259     100,380
Other receivables and prepaid expenses         23,600     22,585
Inventories         148,047     144,595
TOTAL CURRENT ASSETS         1,461,748     1,896,635
Long-term deposits and marketable securities         260,426     225,639
Property, plant and equipment, net         197,896     193,727
Deferred income taxes         118,915     87,257
Other assets         30,533     29,952
TOTAL ASSETS       $ 2,069,518   $ 2,433,210
             
LIABILITIES AND SHAREHOLDERS' EQUITY            
CURRENT LIABILITIES:            
Trade payables       $ 32,500   $ 25,697
Other current liabilities         186,139     190,059
TOTAL CURRENT LIABILITIES         218,639     215,756
Deferred taxes and other long-term liabilities         5,360     7,055
TOTAL LIABILITIES         223,999     222,811
             
Taro shareholders' equity         1,839,976     2,205,158
Non-controlling interest         5,543     5,241
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY       $ 2,069,518   $ 2,433,210
             

 

 
 
TARO PHARMACEUTICAL INDUSTRIES LTD.
SUMMARY CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(U.S. dollars in thousands)
             
       

Nine Months Ended December 31,

        2018   2017
Cash flows from operating activities:            
Net income       $ 223,646     $ 123,651  
Adjustments required to reconcile net income to net cash provided by operating activities:            
Depreciation and amortization         13,738       12,022  
Realized gain on sale of marketable securities and long-lived assets         18       96  
Change in derivative instruments, net         5,881       (4,641 )
Effect of change in exchange rate on inter-company balances, marketable securities and bank deposits         (49,688 )     56,903  
Deferred income taxes, net         741       61,540  
(Increase) decrease in trade receivables, net         (18,439 )     6,704  
Increase in inventories, net         (6,795 )     (5,261 )
Decrease (increase) in other receivables, income tax receivable, prepaid expenses and other         86,425       (28,957 )
Decrease in trade, income tax, accrued expenses, and other payables         8,810       3,513  
Loss from marketable securities, net         792       225  
Net cash provided by operating activities         265,129       225,795  
             
Cash flows from investing activities:            
Purchase of plant, property & equipment, net         (19,526 )     (17,742 )
Investment in other intangible assets         (2,669 )     (1,608 )
Proceeds from short-term bank deposits, net         225,503       225,895  
Proceeds from long-term deposits and other assets         70,685       187,725  
Proceeds from (investment in) marketable securities, net         24,742       (598,578 )
Net cash provided by (used in) investing activities         298,735       (204,308 )
             
Cash flows from financing activities:            
Purchase of treasury stock         (72,191 )     (54,921 )
Dividends paid         (500,000 )      
Net cash used in financing activities         (572,191 )     (54,921 )
             
Effect of exchange rate changes on cash and cash equivalents         (1,815 )     2,228  
Decrease in cash and cash equivalents         (10,142 )     (31,206 )
Cash and cash equivalents at beginning of period         576,611       600,399  
Cash and cash equivalents at end of period       $ 566,469     $ 569,193  
             
Cash Paid during the year for:            
Income taxes       $ 51,487     $ 42,636  
Cash Received during the year for:            
Income taxes       $ (78,367 )   $ (44 )
Non-cash investing transactions:            
Purchase of property, plant and equipment included in accounts payable       $ 1,544     $ 1,390  
Non-cash financing transactions:            
Purchase of treasury stock       $ 4,493     $ 781  
Purchase of marketable securities       $ 1,799     $  

 

 

 


Click here for Media Contact Details
CONTACTS :

Mariano Balaguer
VP, Chief Financial Officer
(914) 345-9001
Mariano.Balaguer@Taro.com

William J. Coote
AVP, Business Finance, Treasurer and Investor Relations
(914) 345-9001
William.Coote@Taro.com


More News from Taro Pharmaceutical Industries Ltd.

08/02/2019 3:41PM

टैरो ने 31 दिसंबर 2018 तक के वित्तीय परिणाम मुहैया कराए

टैरो फार्मास्यूटिकल इंडस्ट्रीज लिमिटेड (एनवाईएई:टैरो) (“टैरो या “कंपनी”) ने आज 31 दिसंबर 2018 को समाप्त तिमाही और नौ महीने के अनअंकेक्षित वित्तीय परिणाम मुहैया कराए। 31 दिसंबर 2018 ...

02/02/2019 12:30PM

तीसरी तिमाही के परिणामों की घोषणा टैरो 6 फरवरी 2019 को करेगा

टैरो फार्मास्यूटिकल इंडस्ट्रीज लिमिटेड (एनवाईएसई: टैरो) ने आज एलान किया कि उसकी योजना 31 दिसंबर 2018 को समाप्त तिमाही के अपने वित्तीय नतीजों की घोषणा बुधवार, 6 फरवरी 2019 को बाजार बंद होने के बाद ...

01/02/2019 3:35PM

Taro to Announce Third Quarter Results on February 6, 2019

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the quarter ended December 31, 2018, after the close of market on Wednesday, February 6, ...

Similar News

20/02/2019 4:47PM Image

Duracell Ultra Provides Increased Power to You and Your Devices

Today, Duracell, the world’s #1 alkaline battery company and the power behind many of the nation’s favourite household devices, introduces a new alkaline battery that provides up to 100% more power* - Duracell Ultra.

No Image

20/02/2019 1:15PM

Trivitron Healthcare’s Radiology Division, Kiran Medical Systems, Ventures into Color Doppler Segment

Kiran Medical Systems, the radiology division of Trivitron Healthcare, has ventured into Color Doppler Ultrasound with the launch of Kiran SonoRad V9 Color Doppler in India.